Last reviewed · How we verify
1PC002
This drug is a small molecule that targets the PI3K/AKT/mTOR pathway.
This drug is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | 1PC002 |
|---|---|
| Also known as | Pitavastatin |
| Sponsor | Orient Pharma Co., Ltd. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of downstream targets, including AKT and mTOR, resulting in anti-tumor effects.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1PC002 CI brief — competitive landscape report
- 1PC002 updates RSS · CI watch RSS
- Orient Pharma Co., Ltd. portfolio CI